A study of the new drug CS231295 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new oral drug (CS231295) for people with advanced solid tumors who have run out of standard options. It aims to see how safe the drug is and how well it controls the cancer, and may slow tumor growth. You must be in reasonably good health with adequate organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor (for example, in the lung, pancreas, breast, or liver) that has spread or cannot be removed by surgery, and standard treatments have stopped working or you could not tolerate them.
- You must have at least one measurable tumor that can be seen on scans.
- You should be able to take care of yourself (no or mild symptoms from your cancer).
- You must have adequate kidney, liver, and bone marrow function (the study team will check this with blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.